| Title |
The challenges associated with molecular targeted therapies for glioblastoma
|
|---|---|
| Published in |
Journal of Neuro-Oncology, February 2016
|
| DOI | 10.1007/s11060-016-2080-6 |
| Pubmed ID | |
| Authors |
Toni Rose Jue, Kerrie L. McDonald |
| Abstract |
Glioblastoma (GBM) is the most aggressive malignant brain tumor in adults. Improvements in the treatment of GBM have remained static since the advent of the standard therapy which includes radiation with concurrent and adjuvant temozolomide treatment. Developing treatment and diagnostic or companion biomarker combinations is transforming the way we treat numerous cancers. However, can this emerging paradigm be also effective for GBM? Can GBM be treated the same way as other cancers? Here we review the challenges for a personalized molecular targeted therapeutic approach in GBM. The specific challenges for establishing a personalized molecular targeted medicine program for GBM patients include overcoming the blood brain barrier, unravelling the intra- and inter-heterogeneity that exists and the importance of developing more relevant animal models that recapitulate a patient's GBM tumor. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Unknown | 79 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 20 | 25% |
| Student > Master | 12 | 15% |
| Researcher | 9 | 11% |
| Student > Bachelor | 6 | 8% |
| Student > Postgraduate | 5 | 6% |
| Other | 14 | 18% |
| Unknown | 14 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 25% |
| Biochemistry, Genetics and Molecular Biology | 14 | 18% |
| Agricultural and Biological Sciences | 11 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 9% |
| Neuroscience | 5 | 6% |
| Other | 6 | 8% |
| Unknown | 17 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 February 2017.
All research outputs
#14,255,539
of 22,858,915 outputs
Outputs from Journal of Neuro-Oncology
#1,804
of 2,974 outputs
Outputs of similar age
#156,761
of 298,746 outputs
Outputs of similar age from Journal of Neuro-Oncology
#19
of 39 outputs
Altmetric has tracked 22,858,915 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,974 research outputs from this source. They receive a mean Attention Score of 4.2. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 298,746 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.